Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.
about
Sex and laterality differences in parkinsonian impairment and transcranial ultrasound in never-treated schizophrenics and their first degree relatives in an Andean populationCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewDetection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.Genetics of schizophrenia: from animal models to clinical studiesTardive dyskinesia: therapeutic options for an increasingly common disorder.Motor deficits and schizophrenia: the evidence from neuroleptic-naïve patients and populations at riskSpontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study.SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.Movement disorders in neuroleptic-naïve patients with schizophrenia spectrum disordersThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Effects of two commonly found strains of influenza A virus on developing dopaminergic neurons, in relation to the pathophysiology of schizophrenia.Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.Aripiprazole versus haloperidol treatment in early-stage schizophrenia.Teaching trainees to negotiate research collaborations with industry: a mentorship model.A survey of the tardive dyskinesia induced by antipsychotic drugs in patients with schizophrenia.Spontaneous parkinsonisms and striatal impairment in neuroleptic free youth at ultrahigh risk for psychosis.Impaired implicit learning in schizophrenia.Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial.Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology.Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review.Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychoticsShould long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.Involuntary movements and their correlates in first-episode psychoses.Guidelines for the Pharmacotherapy of Schizophrenia in Adults.Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients.Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophreniaExtrapyramidal examinations in psychiatry.Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia.Prediction of Neurocognitive Deficits by Parkinsonian Motor Impairment in Schizophrenia: A Study in Neuroleptic-Naïve Subjects, Unaffected First-Degree Relatives and Healthy Controls From an Indigenous Population.Early prediction of blonanserin response in Japanese patients with schizophrenia.The field of schizophrenia: strengths, weaknesses, opportunities, and threats.Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders.Spontaneous parkinsonism in antipsychotic-naive patients with first-episode psychosis.Negative symptoms in first episode non-affective psychosis.Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
P2860
Q27303919-BFD5AF56-BB36-46D8-9A31-D4805493C308Q28079821-D0B0C179-B60F-405B-8E45-33265DE85B81Q30373174-0A9D8E6F-DEFD-4BF3-A9D8-5AE9BF3C1801Q30532039-7DC26E0A-1D30-43BB-8626-2902087D6F81Q30566749-16D9D41C-6FE5-405A-84A9-B883198EF56DQ33749524-40F987FA-7FA3-45D6-A5E2-B6369462F4D9Q34048566-11BF48D5-02CC-40CF-BAC1-339EC1E78457Q34067137-DEA32353-9542-4116-8041-D6765C5E07A1Q34145800-D33EE8CF-4ABE-491D-8888-FFC624E7D675Q34332973-5DCAD49E-B1C5-4399-806B-475625FA3364Q34418847-AE4ECAEE-CD9C-482D-A9FE-B26DAA6B9E03Q34516073-1F20DF0F-E178-4A08-A697-6BC99D166603Q34574179-E32C245B-5BCC-4C25-9A6A-541230C21E77Q34651191-6C919E7F-FE29-44DA-961C-9BC700B8E1FEQ35684487-091FD018-2924-446A-B8C3-0562B3F8E31AQ35920534-EAE7CAE6-1FF1-4953-8EFE-02B82B47B303Q36092493-259C51ED-C601-47C8-B991-76601B07E901Q36311806-2F3EF342-549C-49FF-A075-DA998E33E11FQ36901537-6AEB089A-3931-4E1F-AB7E-49F6746F97EBQ37160642-40F7AFCE-05A9-4E18-9825-B3E98EB4A1C7Q37268590-1F037A05-B270-41DD-86EF-5CD01325FCF4Q37322658-C5EB1BA5-64C2-4A5B-BE87-BB4DF70D9419Q37409087-EB0BC927-69F4-4653-9A85-DD4A61E6DA3BQ38064842-2DD65F09-F67A-43CB-A725-F01B482F68E7Q38275273-67C18BB9-CC42-4316-8C49-F5B09114302BQ39432209-1B6269E5-607D-4348-B7E5-683F0C6F5731Q40792368-940D8C99-004E-4716-B3B2-E2DF10AF4E4FQ41579267-29D1C9B6-6DF8-4CA3-BDF7-A36F0DD168FBQ41592066-387C0753-AD33-44F1-A97A-37404785FF7FQ41819903-9E3935C7-8BA8-4CE1-A3A6-915822F47586Q42517435-5A471A12-01F1-4A42-BFC5-314EA4612A98Q42650152-93EB219C-8ED3-4949-8205-91996BC33598Q42924056-2DDA73DB-58B2-4CE6-A531-3DF9B4E913B8Q43032610-6E32F2E4-9AD3-4C16-9213-70D7ECA9432AQ43228765-CCEF5894-2AE0-4EBB-8E44-C4527F5CFF9FQ43624360-58748578-07A6-4293-A45E-D6905887DDB2Q44024286-0DD45A1A-CA31-4BE2-987E-E0D6C390120EQ44407173-A966583B-7B83-42B4-9CB1-38249E412C51Q44580793-C39FCF5E-79AF-4B7D-80F8-1CFFC611A48AQ46486034-B52524D1-13D3-4F67-8971-542124A6CF16
P2860
Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Prevalence and clinical correl ...... icated schizophrenic patients.
@ast
Prevalence and clinical correl ...... icated schizophrenic patients.
@en
Prevalence and clinical correl ...... icated schizophrenic patients.
@nl
type
label
Prevalence and clinical correl ...... icated schizophrenic patients.
@ast
Prevalence and clinical correl ...... icated schizophrenic patients.
@en
Prevalence and clinical correl ...... icated schizophrenic patients.
@nl
prefLabel
Prevalence and clinical correl ...... icated schizophrenic patients.
@ast
Prevalence and clinical correl ...... icated schizophrenic patients.
@en
Prevalence and clinical correl ...... icated schizophrenic patients.
@nl
P2093
P921
P356
P1476
Prevalence and clinical correl ...... icated schizophrenic patients.
@en
P2093
Chatterjee A
Lieberman JA
Sheitman B
P304
P356
10.1176/AJP.152.12.1724
P407
P577
1995-12-01T00:00:00Z